Open Access Highly Accessed Open Badges Meeting report

Stem cells and cancer immunotherapy: Arrowhead’s 2nd annual cancer immunotherapy conference

Adrian Bot1*, Maurizio Chiriva-Internati2, Andrew Cornforth3, Brian J Czerniecki4, Soldano Ferrone5, Kenneth Geles6, Philip D Greenberg7, Elaine Hurt8, Richard C Koya9, Masoud H Manjili10, William Matsui11, Richard A Morgan12, Claudia M Palena12, Daniel J Powell Jr4, Nicholas P Restifo12, David M Spencer13, Raul Vizcardo14, Albert J Wong15, Lili Yang16 and John Yu17

Author Affiliations

1 Kite Pharma Inc., 2225 Colorado Avenue, Santa Monica, CA 90404, USA

2 Texas Tech University of Health Sciences Center School of Medicine, Lubbock, TX, USA

3 California Stem Cell, Inc., Irvine, CA, USA

4 University of Pennsylvania, Philadelphia, PA, USA

5 Harvard Medical School, BostonMA, USA

6 Pfizer Inc., New york, NY, USA

7 Fred Hutchinson Cancer Research Center, Seattle, WA, USA

8 MedImmune, Gaithersburg, MD, USA

9 Roswell Park Cancer Institute, Buffalo, NY, USA

10 Virginia Commonwealth University School of Medicine, Massey Cancer Center, Richmond, VA, USA

11 Johns Hopkins University School of Medicine, Baltimore, MD, USA

12 National Cancer Institute, Bethesda, MD, USA

13 Bellicum Pharmaceuticals, Inc, Houston, TX, USA

14 RIKEN Research Center for Allergy and Immunology, Yokohama, Japan

15 Stanford University Medical Center, Stanford, CA, USA

16 University of California, Los Angeles, CA, USA

17 Immunocellular Therapeutics, Calabasas, CA, USA

For all author emails, please log on.

Journal for ImmunoTherapy of Cancer 2014, 2:6  doi:10.1186/2051-1426-2-6

Published: 20 March 2014


Investigators from academia and industry gathered on April 4 and 5, 2013, in Washington DC at the Arrowhead’s 2nd Annual Cancer Immunotherapy Conference. Two complementary concepts were discussed: cancer “stem cells” as targets and therapeutic platforms based on stem cells.

Immunotherapy; Cancer stem cells; Hematopoietic stem cells; Adoptive T cell therapy; Antibodies; Vaccines